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conomic  assessment  of coronary  stenting  in patients
ith ST elevation  myocardial  infarction  in Colombia:
 step  toward  policy  implementation
valuación  económica  de  stents  coronarios  en  pacientes  con  infarto  del
iocardio  con  elevación  del  ST  en  Colombia:  un  paso  hacia  la
mplementación  de  políticas
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ontrol  of  health  care  expenditure  remains  one  of  the  most
igniﬁcant  challenges  many  countries  in  the  world  are  cur-
ently  facing  given  its  potential  to  disrupt  the  provision  of
asic  health  care  services  within  the  next  decade.  As  seen
n  this  graphic  from  the  World  Bank  (Fig.  1),  health  expendi-
ure  per  capita  in  Colombia  has  followed  the  same  upward
rend  seen  in  most  developed  and  developing  countries.1
Since  cardiovascular  disease  remains  the  leading  cause  of
orbidity  and  mortality,  any  large  scale  interventions  will
ave  a  signiﬁcant  impact  in  healthcare  budgets.
Cost-effectiveness  analysis  is  a  tool  which  provides  dif-
erent  costs  associated  with  health  outcomes,  compares
osts  of  treatment  alternatives  and  assesses  which  alterna-
ive  is  worth  the  cost.  This  information  will  provide  policy
akers  elements  for  allocation  decisions.  The  goal  is  to
et  the  most  out  of  the  existing  and  projected  ﬁnancial
esources.Quality-adjusted  life  year,  or  QALY,  reﬂects  how  many
ears  of  high-quality  life  a  patient  gains  with  a  particular
ntervention.  Another  parameter  used  to  measure  value  is
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120-5633/© 2014 Sociedad Colombiana de Cardiología y Cirugía Cardiovhe  cost-effectiveness  ratio.  It  is  the  price  of  buying  more
ealthy  years  with  a new  treatment  compared  with  the
tandard  treatment,  and  whether  it  is  a  good  value.
The  World  Health  Organization  has  a  rule  of  thumb:
hree  times  per-person  income  per  quality-adjusted  life
ear  gained  is  a  cost-effective  intervention.
To  make  further  progress  in  health,  meet  new  challenges,
nd  redress  inequities,  resources  must  be  deployed  effec-
ively.  This  requires  knowledge  about  which  interventions
ctually  work,  information  about  how  much  they  cost,  and
xperience  with  their  implementation  and  delivery
In  this  issue  of  the  Revista  Colombiana  de  Cardiología,
.  Ceballos-González2 published  an  elegant  cost  effective-
ess  analysis  of  drug  eluting  stents  (DES)  compared  to
are  metal  stents  in  patients  with  ST  elevation  myocardial
nfarction  (STEMI)  in  Colombia.  His  analyses  included  actual
osts,  projected  costs,  probability  determinations  as  well  as
any  others  calculations  which  are  rather  difﬁcult  to  trans-
ate  into  clinical  language.  The  main  conclusion  however,
as  that  Sirolimus-eluting  stents  are  not  cost  effective  for
atients  with  ST  elevation  myocardial  infarction  in  Colom-
ia.It  is  important  to  remember  that  this  analysis  is  circum-
cribed  to  STEMI  patients  and  does  not  apply  to  elective  or
emi  elective  interventions.  Prevalence  has  a  large  effect  on
he  cost-effectiveness  analysis.  For  example,  screening  and
ascular. Published by Elsevier España, S.L.U. All rights reserved.
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Figure  1  Graphic  from  the  World  Bank.
treatment  for  helicobacter,  a  bacterial  risk  factor  for  stom-
ach  cancer,  is  not  cost-effective  in  the  United  States,  but  it  is
cost-effective  in  Colombia,  because  the  prevalence  of  stom-
ach  cancer  is  higher  in  this  country  and  many  of  the  costs  of
treatment  are  lower.  Thus,  it  is  important  not  to  necessarily
extrapolate  the  results  of  STEMI  to  elective  or  semi-elective
stenting  as  the  prevalence  and  rate  of  complications  are  dif-
ferent.  Additionally,  patient  and  lesion  characteristics  may
be  more  relevant  when  determining  the  choice  of  stents,
bare  vs  drug  eluting,  than  the  actual  consideration  of  coro-
nary  artery  disease  prevalence.
Price  evolution  may  also  make  the  difference  between
cost  effective  and  not  cost  effective.  A  study  published  by
Barone-Rochette  et  al.3 found  that  the  sirolimus  stents  were
not  cost  effective  in  2008  but  became  cost  effective  by  2012
after  its  price  was  reduced.
As  a  health  policy,  the  recommendation  to  avoid  DES
in  the  setting  of  STEMI  in  Colombia  may  seem  reasonable
from  the  economic  standpoint.  It  is  however  important  to
remember  that  policies  are  guidelines  and  do  not  necessar-
ily  apply  to  every  case  scenario.  When  making  the  decision
to  use  drug-eluting  vs  bare-metal  stents  is  important  to
make  individual  patient  considerations  such  as  patient’sevation  myocardial  infarction  in  Colombia  e11
ompliance,  type  of  lesion,  concurrent  illnesses  that  may
ncrease  the  risk  of  restenosis  (diabetics),  etc.  In  this  study,
ate  complications  outweighed  the  initial  beneﬁt  of  DES.
hether  late  complications  were  due  to  lack  of  compliance
ith  anti  platelet  therapy  for  instance  may  not  be  excluded.
This  study  may  help  create  the  momentum  toward  delin-
ating  health  policies  around  the  management  of  STEMIs
hich  will  help  standardize  treatments  across  regions  and
enters.  There  are  wide  variations  in  how  often  doc-
ors  order  tests,  prescribe  medicines,  do  procedures  or
urgeries----not  just  in  different  parts  of  the  country,  but  in
ospitals  that  are  right  next  to  each  other.  One  place  may
o  more  procedures  of  a  particular  kind  than  the  place  next
oor.
If  we  could  make  the  high-spending/poor-performance
ospitals  or  regions  or  service  areas  more  like  the  lower-
pending/better-outcome  ones,  the  health  care  system
ould  save  money  and  improve  health  at  the  same
ime.
If  there  is  a  lesson  to  be  learned  from  the  US  health  care
ystem  is  that  elevated  health  care  costs  are  not  sustainable
n  the  long  run  and  ﬁnding  the  balance  between  costs  and
utcomes  will  beneﬁt  both  patients  and  providers.
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